Serum Galectin-3 and ST2 as predictors of unfavorable outcome in stable dilated cardiomyopathy patients

• Main Authors: Celina Wojciechowska, Ewa Romuk, Ewa Nowalany-Kozielska, Wojciech Jacheć
• Format: Article
• Language: English
• Published: Elsevier 2017-09-01
• Series: Hellenic Journal of Cardiology
• Subjects: ST-2; Gaectin-3; Heart failure; Dilated cardiomyopathy
• Online Access: http://www.sciencedirect.com/science/article/pii/S1109966616302494

Dilated cardiomyopathy (DCM) is the third cause of heart failure and the most frequent cause of heart transplantation (HT). The value of biomarkers in prognostic stratification may be important to identification the patients for more advanced treatment. Assessment of serum Galectin-3 (Gal-3) and ST2 as biomarkers of unfavorable outcome (death and combined endpoint: HT or death or left ventricular assist device implantation) in stable DCM patients. 107 DCM patients age 39–56 years were included into the study and followed-up for mean 4.8 years. Gal-3 and ST2 concentrations were measured ELISA tests. Clinical data, treatment, laboratory parameters, NT-proBNP, Gal-3 and ST2 measured at time of inclusion were assessed as risk factors for reaching the study endpoints using log rank test and Cox proportional-hazards model. During follow-up 27 patients died, 40 achieved combined endpoint. ROC curves indicated cut-off value of ST2-17.53 ng/ml, AUC-0.65 (0.53–0.76) and of NT-proBNP-669 pg/ml, AUC 0.61 (0.50–0.73) for prediction of death. In multivariate analysis ST2 was predictor of death (HR per unit increase in log ST2 2.705, 95 % CI 1.324–5.528, P=0.006) and combined endpoint (HR per unit increase in log ST2 2.753, 95 % CI 1.542–4.914, P<0.001). NT-proBNP was predictive variable only for death in multivariate analysis. Gal-3 concentration was not associated with adverse outcome. ST2 but not Gal-3 may be useful for predicting adverse outcome in stable dilated cardiomyopathy patients.